Roche's shares fell dramatically following reports of significant side effects from its obesity pill, raising concerns about its position in a booming weight-loss market.
Roche's study revealed high side effects like nausea and vomiting, with patients who increased doses quickly experiencing even more severe reactions, which could hinder its competition.
Analyst Emily Field noted the challenges ahead for Roche, estimating that the company's anticipated obesity drug might not be on the market until 2030.
Investors are cautious and waiting for more comprehensive data on Roche's obesity pill, as competition heats up with established players Novo Nordisk and Eli Lilly.
Collection
[
|
...
]